SOURCE: Gene Express, Inc.

November 09, 2006 09:22 ET

Gene Express CEO Gerald Vardzel Interviewed by Wall Street Reporter

TOLEDO, OH -- (MARKET WIRE) -- November 9, 2006 -- Gene Express, Inc. today announced that CEO Gerald Vardzel was interviewed yesterday by Wall Street Reporter. The audiocast can be accessed today at the following Internet link:

Mr. Vardzel discussed the Company's mission, proprietary technology platform and value for investors.

Gene Express recently announced a licensing agreement with Gene Logic Inc. for its patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction™) and SEM Center™ (Standardized Expression Measurement Center™) technology for the standardized measurement of gene expression.

StaRT-PCR is a unique method of measuring transcript abundance that incorporates proprietary reagents known as SMIS™ (Standardized Mixture of Internal Standards) that provide integrated quality control for each measurement. StaRT-PCR meets all of the analytical performance characteristics required by the U.S. Food and Drug Administration (FDA) to support pharmacogenomic data submissions in support of clinical trials. StaRT-PCR also meets the criteria defined by the Clinical Laboratory Improvement Amendment of 1988 (CLIA) to support the use of genomic biomarkers for diagnostic testing.

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcriptase Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, tissue and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439
    E: Email Contact